The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)

被引：0
|
作者：
Toshihiko Doi
Yutaka Fujiwara
Kohei Shitara
Toshio Shimizu
Kan Yonemori
Nobuaki Matsubara
Izumi Ohno
Takahiro Kogawa
Yoichi Naito
Lance Leopold
Mihaela Munteanu
Naoyoshi Yatsuzuka
Shi Rong Han
Ayman Samkari
Noboru Yamamoto
机构：
[1] National Cancer Center Hospital East,Department of Experimental Therapeutics
[2] National Cancer Center Hospital,Department of Experimental Therapeutics
[3] Mitsui Memorial Hospital,Department of Respiratory Medicine
[4] Incyte Corporation,Department of Clinical Oncology
[5] Clinical Development,undefined
[6] MSD K.K. Oncology Science Unit,undefined
[7] Merck & Co.,undefined
[8] Inc.,undefined
来源：
Investigational New Drugs | 2021年 / 39卷
关键词：
Advanced solid tumors; Epacadostat (INCB024360); Japanese; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：152 / 162
页数：10
相关论文
共 50 条
  • [1] The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)
    Doi, Toshihiko
    Fujiwara, Yutaka
    Shitara, Kohei
    Shimizu, Toshio
    Yonemori, Kan
    Matsubara, Nobuaki
    Ohno, Izumi
    Kogawa, Takahiro
    Naito, Yoichi
    Leopold, Lance
    Munteanu, Mihaela
    Yatsuzuka, Naoyoshi
    Han, Shi Rong
    Samkari, Ayman
    Yamamoto, Noboru
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (01) : 152 - 162
  • [2] INCB024360 (Epacadostat) monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: primary results from first-in-Japanese phase I study (KEYNOTE-434)
    Fujiwara, Yutaka
    Shitara, Kohei
    Shimizu, Toshio
    Yonemori, Kan
    Matsubara, Nobuaki
    Ohno, Izumi
    Kogawa, Takahiro
    Naito, Yoichi
    Leopold, Lance
    Sasahara, Kahori
    Yatsuzuka, Naoyoshi
    Takami, Tomoko
    Shimamoto, Takashi
    Yamamoto, Noboru
    Doi, Toshihiko
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [3] KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer
    Yamamoto, Noboru
    Satouchi, Miyako
    Doi, Toshihiko
    Fujiwara, Yutaka
    Yanagitani, Noriko
    Kawa, Yoshitaka
    Yoh, Kiyotaka
    Leopold, Lance
    Munteanu, Mihaela
    Sawada, Takashi
    Han, Shirong
    Noguchi, Kazuo
    Nishio, Makoto
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (03) : 261 - 271
  • [4] Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study
    Powderly, John D.
    Klempner, Samuel J.
    Naing, Aung
    Bendell, Johanna
    Garrido-Laguna, Ignacio
    Catenacci, Daniel V. T.
    Taylor, Matthew H.
    Lee, James J.
    Zheng, Fred
    Zhou, Feng
    Gong, Xiaohua
    Gowda, Hema
    Beatty, Gregory L.
    ONCOLOGIST, 2022, 27 (11): : 905 - E848
  • [5] Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors
    Luke, Jason J.
    Fakih, Marwan
    Schneider, Charles
    Chiorean, E. Gabriela
    Bendell, Johanna
    Kristeleit, Rebecca
    Kurzrock, Razelle
    Blagden, Sarah P.
    Brana, Irene
    Goff, Laura W.
    O'Hayer, Kevin
    Geschwindt, Ryan
    Smith, Michael
    Zhou, Feng
    Naing, Aung
    BRITISH JOURNAL OF CANCER, 2023, 128 (12) : 2227 - 2235
  • [6] Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors
    Jason J. Luke
    Marwan Fakih
    Charles Schneider
    E. Gabriela Chiorean
    Johanna Bendell
    Rebecca Kristeleit
    Razelle Kurzrock
    Sarah P. Blagden
    Irene Brana
    Laura W. Goff
    Kevin O’Hayer
    Ryan Geschwindt
    Michael Smith
    Feng Zhou
    Aung Naing
    British Journal of Cancer, 2023, 128 : 2227 - 2235
  • [7] A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.
    Burris, Howard A.
    Patel, Manish R.
    Cho, Daniel C.
    Clarke, Jeffrey Melson
    Gutierrez, Martin
    Zaks, Tal Z.
    Frederick, Joshua
    Hopson, Kristen
    Mody, Kinjal
    Binanti-Berube, Alverina
    Robert-Tissot, Celine
    Goldstein, Bree
    Breton, Ben
    Sun, Jing
    Zhong, Shan
    Pruitt, Scott K.
    Keating, Karen
    Meehan, Robert S.
    Gainor, Justin F.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
    Mitchell, Tara C.
    Hamid, Omid
    Smith, David C.
    Bauer, Todd M.
    Wasser, Jeffrey S.
    Olszanski, Anthony J.
    Luke, Jason J.
    Balmanoukian, Ani S.
    Schmidt, Emmett V.
    Zhao, Yufan
    Gong, Xiaohua
    Maleski, Janet
    Leopold, Lance
    Gajewski, Thomas F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (32) : 3223 - +
  • [9] Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study
    Munster, Pamela
    Iannotti, Nicholas
    Cho, Daniel C.
    Kirkwood, John M.
    Villaruz, Liza C.
    Gibney, Geoffrey T.
    Hodi, F. Stephen
    Mettu, Niharika B.
    Jones, Mark
    Bowman, Jill
    Smith, Michael
    Lakshminarayanan, Mani
    O'Day, Steven
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (12): : 2572 - 2584
  • [10] Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037
    Gangadhar, T. C.
    Hamid, O.
    Smith, D. C.
    Bauer, T. M.
    Wasser, J. S.
    Olszanski, A. J.
    Luke, J. J.
    Balmanoukian, A. S.
    Kaufman, D. R.
    Zhao, Y.
    Maleski, J.
    Jones, M. J.
    Leopold, L.
    Gajewski, T. F.
    ANNALS OF ONCOLOGY, 2016, 27
12345